Viridian Therapeutics, Inc. (VRDN) — Dilution Risk Analysis

Current Snapshot

Viridian Therapeutics, Inc. (VRDN) has a DilutionWatch score of 50/10 and is classified as MEDIUM risk. The score date in the source data is 2026-10-03T03:45:52.527348.

This page is assembled from sourced share-structure, market-data, SEC-filing, and DilutionWatch fields. Missing values are left blank rather than estimated.

Share Structure

Shares Outstanding
113,292,269 Source
Public Float
103,020,110 Source
Float as % of Outstanding
90.9%

Dilution Risk Score

Score: 50/10 Source (as of 2026-10-03T03:45:52.527348)

Recent SEC Filings

Recent filing forms in the source payload: 4 7, XBRL 2, 8-K 1.

FormFiledAccession
4 2026-07-02 0001193125-26-294546
4 2026-07-02 0001193125-26-294547
4 2026-07-02 0001193125-26-294552
4 2026-07-02 0001193125-26-294556
4 2026-07-02 0001193125-26-294560
4 2026-07-02 0001193125-26-294561
xbrl 2026-06-30 xbrl-2598-xbrl_convertible
4 2026-05-13 0001104659-26-060294
8-K 2026-05-11 0001193125-26-216709
xbrl 2025-12-31 xbrl-2598-xbrl_warrant

Dilution Risk Drivers

DriverStored ValueSource
Cash runway 6 months Source
Three-year share count growth 115.44% Source

DilutionWatch Analysis

Risk Level
MEDIUM (Score: 50/10) Source
Cash Runway
6 months Source
Share Count Growth (3-Year)
115.44% Source

What This Page Does Not Estimate

DilutionWatch does not infer missing cash runway, authorized share count, ATM capacity, shelf capacity, or share-growth values on this page. A blank field means the current source payload did not provide a usable value with provenance.

Scores and classifications are shown only when supplied by the DilutionWatch data layer. SEC filing rows link to their source accession when a filing URL is available.